Daily Archives: June 23, 2021

FDA Action Alert: Incyte and Ascendis – BioSpace

Posted: June 23, 2021 at 6:44 am

Incyte had a particularly big week scheduled with the U.S. Food and Drug Administration (FDA), which included two PDUFA dates and an advisory committee meeting. In addition, Ascendis had a target action date. However, the agency had a chance of plans. Read on for more information.

Incytes Ruxolitinib Cream for Atopic Dermatitis

Incytehas a target action date of June 21, 2021, for its New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application for atopic dermatitis (AD), a type of eczema. The NDA included data from the Phase III TRuE-AD clinical trial program of more than 1,200 people ages 12 and older. The company submitted a priority review voucher (PRV) with the NDA. The use of the PRV shortens the review period by four weeks. On June 11, the company reported the FDA had extended the review period for the NDA by three months to September 21, 2021. The agency indicated it needed time to review additional analyses the company submitted in response to an information request.

At the companys first-quarter financial report on May 4, Herve Hoppenot, Incytes chief executive officer, said, We expect an exciting year ahead for Incyte with the potential for multiple approvals, including ruxolitinib cream in atopic dermatitis, and several regulatory filings, notably parsaclisib in NHL and ruxolitinib cream in vitiligo. We are also initiating pivotal trials across key development programs for both tafasitamab and LIMBER this year.

Incytes Ruxolitinib for Steroid-Refractory Chronic Graft-Versus-Host Disease

Incyte also has a target action date of June 22 for its supplemental NDA for ruxoliltinib (Jakafi) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. This sNDA is built on data from the Phase III REACH3 trial comparing ruxolitinib with best available therapy (BAT) in this patient population. In that study, patients receiving ruxolitinib had a significantly greater overall response rate (ORR) compared to BAT at Week 24, which was the primary endpoint of the study. The ORR was 49.7% in the ruxolitinib group compared to 25.6% in the BAT cohort. On June 8, 2021, Incyte announced the FDA had also extended the review period for the sNDA for Jakafi for this indication until September 22, 2021. Again, it was in response to additional information submitted as part of an FDA information request.

Chronic GVHD is a life-threatening complication following stem cell transplant that burdens a vulnerable patient population, which today has limited treatment options, said Peter Langmuir, Group Vice President, Oncology Targeted Therapies, Incyte, in a February 2021 statement. The acceptance of this sNDA represents an important milestone for Incyte as we continue our work towards helping more people living with GVHD, particularly for those who do not respond to steroids. We look forward to working closely with the FDA to bring this innovative therapy to patients and to providing continued support to the GVHD community in the United States.

FDAs AdCom to Review Incytes BLA for Retifanlimab Injection for Anal Cancer

In what is clearly a busy week for Incyte, the FDAs Oncologic Drugs Advisory Committee is holding a meeting on June 24 to discuss the companys Biologics License Application (BLA) for retifanlimab injection for the treatment of adults with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy.

The BLA was accepted for Priority Review on January 21, 2021, and has a target action date of July 25, 2021. The submission was based on data from the Phase II POD1UM-202 trial. It enrolled 94 patients, including several with well-controlled HIV infection. There was an ORR of 14% for retifanlimab monotherapy.

Patients with SCAC who have progressed after first-line chemotherapy treatment currently have no approved treatments available, and we are encouraged that the FDAs acceptance of this BLA for Priority Review brings us one step closer to addressing this historically neglected, yet important, tumor, said Lance Leopold, Group Vice President, Immuno-Oncology Clinical Development, Incyte, in a January 21 statement. Despite SCAC being a rare disease, its incidence is increasing, and its impact is profound. We look forward to working with the FDA to potentially fill an unmet need and advance progress in SCAC for patients.

Ascendiss TransCon hGH for Pediatric GHD

Ascendis Pharmahas a target action date of June 25 for its BLA of TransCon hGH (lonapegsomatropin) for the treatment of pediatric Growth Hormone Deficiency (GHD). The drug is designed to release somatropin with the same action and distribution as once-a-day somatropin products, but with a once-a-week injection. The BLA is based on a clinical development program including eight clinical trials in more than 400 patients with GHD. In pediatric GHD, the pituitary gland does not generate enough growth hormone. The children are short, but may also experience metabolic abnormalities, psychosocial challenges and poor quality of life. The standard of care for GHD is a daily subcutaneous injection of hGH. On June 11, the FDA pushed back the PDUFA date until September 25, 2021. Ascendis indicated, like with the previous Incyte announcements, that after an FDA information request, the agency decided it was a major amendment and extended the target action date in order to provide more time to review the data.

During the companys first-quarter financial report on May 27, Jan Mikkelson, Ascendis Pharmas president and chief executive officer stated, With potential U.S. FDA approval for TransCon hGH now less than a month away, we believe we are one step closer to fulfilling our Vision 3x3 to build a leading biopharma company. Guided by our values of patients, science and passion, we have built a pipeline of three differentiated endocrinology rare disease product candidates by applying our TransCon technology to clinically validated parent drugs and/or targets. Each candidate targeting substantial unmet medical needs in larger markets where we have the potential to become the market leader.

At the new deadline, Mikkelsen stated, We have responded to all outstanding questions from the FDA and believe the complete package we have submitted satisfies all of FDAs requests and will enable a complete review of the application of lonapegsomatropin for pediatric GHD. We are committed to making lonapegsomatropin the market-leading therapy for treating pediatric GHD and look forward to continuing interactions with the FDA during the remainder of the review process.

See the article here:
FDA Action Alert: Incyte and Ascendis - BioSpace

Posted in Eczema | Comments Off on FDA Action Alert: Incyte and Ascendis – BioSpace

On the 40th anniversary of Wayne Williams arrest, Atlanta police receive funding for DNA testing – 11Alive.com WXIA

Posted: at 6:44 am

The next date Wayne Williams will be considered for parole is November 2027.

ATLANTA The Atlanta Police Department said it now has the approved funding to begin retesting DNA evidence in the Atlanta Child Murders case. Monday marked 40 years since the longtime suspected killer, Wayne Williamswas arrested in two adults' unrelated deaths.

The Atlanta Child Murders case returned to national headlines in 2019, when police reopened the haunting case nearly 40 years after the tragic killing spree began.

Williams,considered the prime suspect in the Atlanta Child Murders case, has been behind bars since June 21, 1981. He was convicted in 1982 for the murder of two adult men unrelated to the child murders. But he was never charged in the killing spree that would become one of the most notorious cases in U.S. history, even though Williams is the only suspect investigators have ever made known publicly.

Forty years ago, investigators were limited by technology.

When the case reopened two years ago, the city made a promise to test all possible DNA evidence in the child murders.

APD released a statement Monday saying the following:

As part of the reopened Missing and Murdered Children investigation, Atlanta Police Homicide Investigators have compiled evidence to be submitted for DNA testing. The funding needed to move forward with the testing was approved today, June 21, 2021, and we are in the process of coordinating with the vendor to submit the evidence and make payment for the testing. At this time, the investigation remains open.

The Fulton County District Attorney's Office also previously announced it was launching a conviction integrity unit as a way to re-examine prior convictions including Williams case.

The D.A,s office said on Monday that Shelia Ross, a specially sworn Assistant District Attorney and veteran homicide prosecutor, has been brought in to lead the review and work with our law enforcement partners on those cases.

Investigators have believed Williams is the key suspect in the Atlanta child murders, even as Williams has insisted hes innocent. Over the years, other theories have been floated. But to this day, no one has stood trial in the childrens murders dating back to the late 70s and early 80s.

Williams was up for parole consideration back in 2019, and the board denied the parole request. The next date he will be considered for parole is November 2027.

View original post here:
On the 40th anniversary of Wayne Williams arrest, Atlanta police receive funding for DNA testing - 11Alive.com WXIA

Posted in DNA | Comments Off on On the 40th anniversary of Wayne Williams arrest, Atlanta police receive funding for DNA testing – 11Alive.com WXIA

LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults…

Posted: at 6:44 am

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,4,5

Adtralza will be available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600 mg followed by 300 mg every other week.1 Adtralza can be used with or without topical corticosteroids (TCS).1

This European Commission approval of Adtralza means that clinicians across Europe now have an important new treatment option for adult patients with moderate-to-severe atopic dermatitis, which is a chronic, unpredictable skin disease, said Stephan Weidinger, MD, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany and tralokinumab clinical trial investigator. By specifically targeting IL-13 with high affinity, Adtralza has demonstrated that it can reduce atopic dermatitis signs and symptoms and sustain improvements over time.

The approval is based primarily on efficacy and safety results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included more than 1,900 adult patients with moderate-to-severe atopic dermatitis.1 Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA 1, 2 and ECZTRA 3, a dose-ranging trial, and a vaccine response trial.1

This European Commission approval of Adtralza is an important development for the millions of adults in Europe who are living with this often uncontrolled skin disease, said Catherine Mazzacco, President and CEO of LEO Pharma. We are proud to have the opportunity to offer a new long-term treatment option for moderate-to-severe atopic dermatitis and are working closely with key stakeholders to enable access to Adtralza for eligible patients.

The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein. Additional regulatory filings are underway with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and other health authorities worldwide.

About Adtralza (tralokinumab)

Adtralza (tralokinumab) is a fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby preventing interaction with the IL-13 receptor 1 and 2 subunits (IL-13R1 and IL-13R2).4,5

About the pivotal ECZTRA 1, 2, and ECZTRA 3 Trials

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational 52-week trials, which included 802 and 794 adult patients, respectively, to evaluate the safety and efficacy of Adtralza (300 mg) as monotherapy in adults with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.2

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week trial, which included 380 adult patients, to evaluate the safety and efficacy of Adtralza (300 mg) in combination with TCS in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.3

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.6 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.7 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.4

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information please visit http://www.LEO-Pharma.com.

References

June 2021 MAT-46806

More here:
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults...

Posted in Eczema | Comments Off on LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults…

Each of These Microscopic Glass Beads Stores an Image Encoded on a Strand of DNA – Singularity Hub

Posted: at 6:44 am

Increasingly, civilizations information is stored digitally, and that storage is abundant and growing. We dont bother deleting those seven high-definition videos of the ceiling or 20 blurry photos of a table corner taken by our kid. Theres plenty of room on a smartphone or in the cloud, and we count on both increasing every year.

As we fluidly copy information from device to device, this situation seems durable. But thats not necessarily true.

The amount of data we create is increasing rapidly. And if we (apocalyptically) lost the ability to produce digital storage deviceshard drives or magnetic tape, for exampleour civilizations collective digital record would begin to sprout holes within years. In decades, itd become all but unreadable. Digital storage isnt like books or stone tablets. It has a shorter expiration date. And, although we take storage for granted, its still expensive and energy hungry.

Which is why researchers are looking for new ways to archive information. And DNA, lifes very own hard drive, may be one solution. DNA offers incredibly dense data storage, and under the right conditions, it can keep information intact for millennia.

In recent years, scientists have advanced DNA data storage. Theyve shown how we can encode individual books, photographs, and even GIFs in DNA and then retrieve them. But there hasnt been a scalable way to organize and retrieve large collections of DNA files. Until now, that is.

In a new Nature Materials paper, a team from MIT and Harvards Broad Institute describe a DNA-based storage system that allows them to search for and pull individual filesin this case images encoded in DNA. Its a bit like thumbing through your file cabinet, reading the paper tabs to identify a folder, and then pulling the deed to your car from it. Only, obviously, the details are bit more complicated.

We need new solutions for storing these massive amounts of data that the world is accumulating, especially the archival data, said Mark Bathe, an MIT professor of biological engineering and senior author of the paper. DNA is a thousandfold denser than even flash memory, and another property thats interesting is that once you make the DNA polymer, it doesnt consume any energy. You can write the DNA and then store it forever.

How does one encode an image in a strand of DNA, anyway? Its a fairly simple matter of translation.

Each pixel of a digital image is encoded in bits. These bits are represented by 1s and 0s. To convert it into DNA, scientists assign each of these bits to the DNAs four base molecules, or nucleotides, adenine, cytosine, guanine, and thymineusually referred to in shorthand by the letters A, C, G, and T. The DNA bases A and G, for example, could represent 1, and C and T could represent 0.

Next, researchers string together (or synthesize) a chain of DNA bases representing each and every bit of information in the original file. To retrieve the image, researchers reverse the process, reading the sequence of DNA bases (or sequencing it) and translating the data back into bits.

The standard retrieval process has a few drawbacks, however.

Researchers use a technique called a polymerase chain reaction (PCR) to pull files. Each strand of DNA includes an identifying sequence that matches a short sequence of nucleotides called a PCR primer. When the primer is added to the DNA solution, it bonds with matching DNA strandsthe ones we want to readand only those sequences are amplified (that is, copied for sequencing). The problem? Primers can interact with off-target sequences. Worse, the process uses enzymes that chew up all the DNA.

Youre kind of burning the haystack to find the needle, because all the other DNA is not getting amplified and youre basically throwing it away, said Bathe.

To get around this, the Broad Institute team encapsulated the DNA strands in microscopic (6-micron) glass beads. They affixed short, single-stranded DNA labels to the surface of each bead. Like file names, the labels describe the beads contents. A tiger image might be labeled orange, cat, wild. A house cat might be labeled orange, cat, domestic. With just four labels per bead, you could uniquely label 1020 DNA files.

The team can retrieve specific files by adding complementary nucleotide sequences, or primers, corresponding to an individual files label. The primers contain fluorescent molecules, and when they link up with a complementary strandthat is, the searched-for labelthey form a double helix and glow. Machines separate out the glowing beads, which are opened and the DNA inside sequenced. The rest of the DNA files remain untouched, left in peace to guard their information.

The best part of the method is its scalability. You could, in theory, have a huge DNA library stored in a test tubeBathe notes a coffee mug of DNA could store all the worlds databut without an easy way to search and retrieve the exact file youre looking for, its worthless. With this method, everything can be retrieved.

George Church, a Harvard professor of genetics and well-known figure in the field of synthetic biology, called it a giant leap for the field.

The rapid progress in writing, copying, reading, and low-energy archival data storage in DNA form has left poorly explored opportunities for precise retrieval of data files from hugedatabases, he said. The new study spectacularly addresses this using a completely independent outer layer of DNA and leveraging different properties of DNA (hybridization rather than sequencing), and moreover, using existing instruments and chemistries.

To be clear, all DNA data storage, including the work outlined in this study, remains firmly in the research phase. Dont expect DNA hard drives for your laptop anytime soon.

Synthesizing DNA is still extremely expensive. Itd cost something like $1 trillion dollars to write a petabyte of data in DNA. To match magnetic tape, a common method of archival data storage, Bathe estimates synthesis costs would have to fall six orders of magnitude. Also, this isnt the speediest technique(to put it mildly).

The cost of DNA synthesis will fallthe technology is being advanced in other areas as welland with more work, the speed will improve. But the latter may be beside the point. That is, if were mainly concerned with backing up essential data for the long term with minimal energy requirements and no need to regularly access it, then speed is less important than fidelity, data density, and durability.

DNA already stores the living worlds information, now, it seems, it can do the same for all things digital too.

Image Credit: Courtesy of the researchers (via MIT News).

Originally posted here:
Each of These Microscopic Glass Beads Stores an Image Encoded on a Strand of DNA - Singularity Hub

Posted in DNA | Comments Off on Each of These Microscopic Glass Beads Stores an Image Encoded on a Strand of DNA – Singularity Hub

Atopic Eczema Treatment Market Projected to Reach USD 34089.3 Million by 2026 – Biophotonics.World

Posted: at 6:44 am

Atopic Eczema Treatment Market

Facts & Factors (FnF) published a market research report onAtopic Eczema Treatment Market By Type (Topical, Oral, and Injectable), By Application (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 2026includes 190+ pages of research PDF with TOC including a list of table and figures in its research offerings.

FnF Research presents an updated and Latest Study onAtopic Eczema Treatment Market2020-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Atopic Eczema Treatment market during the forecast period (2020-2029).

According to the research report, " [195+ Pages Report] Global atopic eczema treatment market size & share estimated to reach USD 34,089.3 Million by 2026, growing at a CAGR of 10.36% between 2020 and 2026. Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. "

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

Request Updated Free Sample Research Report on Atopic Eczema Treatment Market:https://www.fnfresearch.com/sample/atopic-eczema-treatment-market

(The free sample of this report is readily available on request and updated with new research additions).

What benefits does FNF research study is going to provide?

Atopic Eczema Treatment Market by Top Manufacturers (2020-2026)

Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact

Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever.

We at Facts and Factors (www.fnfresearch.com) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients.

Industry study presents the global Atopic Eczema Treatment market size, historical breakdown data (2014-2019), and forecast (2020-2026). Production, revenue, and market share by key vendors, key regions, and type; The consumption of Atopic Eczema Treatment market in terms of volume is also provided for major countries (or regions), and for each application and product at the global level.

Inquire more before buying this report Here:https://www.fnfresearch.com/inquiry/atopic-eczema-treatment-market

Key Answers in the Report

In this study, the years considered to estimate the market size of Atopic Eczema Treatment Market:

Geographically,this report is segmented into severalkey regions, with sales, revenue, market share, and growth rate of Atopic Eczema Treatment in these regions, from 2020 to 2026, covering

Reasons to Buy the Report

Browse detailed report with in-depth TOC @https://www.fnfresearch.com/atopic-eczema-treatment-market

Segmentation

As discussed earlier, there is segmentation in theAtopic Eczema Treatment Marketreport, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Atopic Eczema Treatment Market. At the same time, there is an emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Atopic Eczema Treatment Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of theAtopic Eczema Treatment Marketreport, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows the Middle East and Africa, South and North America, Europe, and the Asia Pacific. From the Atopic Eczema Treatment Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From thisAtopic Eczema Treatment Marketreport, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Atopic Eczema Treatment Market report.

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing a planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

View original post here:
Atopic Eczema Treatment Market Projected to Reach USD 34089.3 Million by 2026 - Biophotonics.World

Posted in Eczema | Comments Off on Atopic Eczema Treatment Market Projected to Reach USD 34089.3 Million by 2026 – Biophotonics.World

Dad and daughter meet for first time in 53 years through DNA testing just in time for Father’s Day – WGAL Lancaster

Posted: at 6:44 am

A father and daughter separated by 53 years and 2,000 miles recently met for the first time thanks to an unexpected DNA match.Deb Scales told KFSN-TV that she initially was interested in researching her nationality."I wanted to know was I mostly Irish or Scottish or English? Or whatnot. The man I thought was my father passed last year, and I was no longer able to give any information from him," Scales told the TV station. "So when I got the results, I reached out and found out that actually that wasn't my dad and Tim Herrick is."Scales initially had an Ancestry DNA match with Herrick's sister.Herrick, who is 78 years old, has been married for 51 years and has three children and a stepson, seven grandchildren and four great-grandchildren.And now his family has grown even bigger.Watch the video above to learn more about this story.

A father and daughter separated by 53 years and 2,000 miles recently met for the first time thanks to an unexpected DNA match.

Deb Scales told KFSN-TV that she initially was interested in researching her nationality.

"I wanted to know was I mostly Irish or Scottish or English? Or whatnot. The man I thought was my father passed last year, and I was no longer able to give any information from him," Scales told the TV station. "So when I got the results, I reached out and found out that actually that wasn't my dad and Tim Herrick is."

Scales initially had an Ancestry DNA match with Herrick's sister.

Herrick, who is 78 years old, has been married for 51 years and has three children and a stepson, seven grandchildren and four great-grandchildren.

And now his family has grown even bigger.

Watch the video above to learn more about this story.

Continue reading here:
Dad and daughter meet for first time in 53 years through DNA testing just in time for Father's Day - WGAL Lancaster

Posted in DNA | Comments Off on Dad and daughter meet for first time in 53 years through DNA testing just in time for Father’s Day – WGAL Lancaster

Home Remedies To Treat Eczema – Powdersvillepost.com

Posted: at 6:44 am

Share

Share

Share

Email

Eczema is characterized by dry, itchy skin that tends to get worst during the winters.

People can often use some natural and home remedies like coconut oil or aloe vera to manage the condition.

These natural substances can moisturize the skin and treat the inflammation and the harmful bacteria to manage the swelling and infection.

Although natural home remedies cannot cure eczema, they can be helpful in managing the condition and providing temporary relief.

Aloe vera gel and apple cider vinegar:

Aloe vera gel can be retrieved from the leaves of the plant. They are being used for centuries to treat a variety of medical conditions.

Aloe vera gel has anti-bacterial, anti-microbial, immunity, and wound healing properties that can soothe the sensitive skin associated with eczema.

To obtain the best result, aloe vera gel that contains the least number of added ingredients is to be chosen; alternatively, one can get aloe plants at home and directly retrieve the gel from its leaves.

In terms of precautionary measures, one should always start with a very small amount of gel to check if the skin is sensitive to it, and alcohol should be avoided to further dry out and irritate the skin

According to the National Eczema Association (NEA), apple cider vinegar can prove to be effective against eczema. However, one should be vigilant about any irritation emerging in the skin due to the acid of the vinegar.

Apple cider vinegar can manage eczema by killing the bacteria causing the infection and maintaining the pH level of the skin.

A bleach bath and colloidal oatmeals:

Although it may seem risky, a bath with bleach can improve the symptoms of eczema, according to expert belief.

Bleach is effective in killing the bacteria responsible for the infection, especially the S. aureus bacteria causing the staph infection.

This restores the natural microbiome profile of the skin and helps in managing the symptoms.

Colloidal oatmeal is another natural remedy known to provide some relief against the painful conditions of eczema.

Colloidal oatmeal is also known as Avena Sativa and is made of oats. For this purpose, oats are grounded and boiled to extract the compounds that have healing properties and can prove to be anti-inflammatory and anti-oxidative in nature.

It can manage the symptoms of eczema by reducing skin dryness, scaling, roughness, and intense itchiness.

Regular baths and use of coconut oil:

Taking regular part is an important part of eczema care and treatment. For improving the condition, one needs proper moisturization of the skin since the natural ability of the skin to moisturize itself is lost.

However, while bathing, one should be conscious about using the wrong soap, using water that is either too hot or too cold and not moisturizing after bath.

According to the guidelines of NEA, those suffering from eczema should bathe once a day using lukewarm water, bathe for only 15-20 minutes and not scrub their skin, use gentle cleansers, and have medicated baths using oatmeal, apple cider vinegar, and baking soda.

Coconut oil is known to help people with eczema and dry skin owing to the presence of beneficial fatty acids in its composition. Virgin coconut oil can reduce skin inflammation by improving the quality of the outer layer of the skin that acts as a protective barrier against infections.

Lifestyle changes that can improve the condition:

Eczema is characterized by inflamed and sore skin. Hence foods that can reduce inflammation helps in managing the condition.

One should include plenty of anti-inflammatory foods in their daily diet. These include fish, leafy greens, lentils, beans, colorful fruits, vegetables, cinnamon, and turmeric.

Whereas one should avoid the intake of inflammatory foods like eggs, dairy, soy, and wheat products.

Furthermore cold and harsh climatic conditions should be avoided as it can dry out the skin and lead to eczema flares, also string dry heat like sitting close to a fireplace should be avoided as hot dry air can worsen the condition by further drying out and irritating the skin.

See the article here:
Home Remedies To Treat Eczema - Powdersvillepost.com

Posted in Eczema | Comments Off on Home Remedies To Treat Eczema – Powdersvillepost.com

Pueblo West resident utilizes massage therapy to heal mind, body and spirit – Pueblo Chieftain

Posted: at 6:44 am

Preventing wildfires

Here are some tips and information on how to prevent wildfires in your life.

Heather Willard, The Pueblo Chieftain

After working on his feet for 8-10 hours a day for more than 13 years, dealing with the everyday aches and pains, and attending night school, Yandi Cakrasenjaya knew he needed to make a change in lifestyle now his journey is just beginning.

That journey ledCakrasenjaya to his current job as a massage therapist at Jara Elements.

Cakrasenjaya was born in Bandung, Indonesia, the oldest of four children.

When his family moved to the United States, Cakrasenjaya was 14-years-old and said without knowing the language or culture, he utilized less traditional routes to learn about his new home.

(My siblings) were younger, so they picked up English pretty quick, Cakrasenjaya said. Im the oldest, I needed to learn. So, I realized what they were doing was they were watching TV, going outside they werent afraid. They come home speaking English, and Im like, What the heck am I doing wrong?

MORE: The Lockwood Foundation in Pueblo West needs volunteers to make the impossible, possible

Cakrasenjaya took a page out of his siblings book, beginning to learn English using the popular childrens show Sesame Street.

While Sesame Street taught him the basics of English the ABCs and how to countattending school helped Cakrasenjaya with proper English.

He noticed outside of the classroom, his classmates were using slang. Thats when he turned to the infamous Die Hard trilogy to improve his knowledge of the language kids around him were using.

After overcoming the adversity through education, Cakrasenjaya entered the workforce. He worked in retail in various positions for 13 years before deciding to attend culinary school.

Cakrasenjaya was working 810-hour days before attending classes, and noticed this lifestyle was not sustainable.

After deciding to make self-care a priority, Cakrasenjaya decided to make a move, leaving behind his home in Iowa and starting fresh in Colorado.

The move inspired a fitness journey that would ultimately lead him to what is now his career and passion.

I was overweight, I was unhappy, I didnt watch what I ate, so I would wake up angry, Cakrasenjaya said. But when I moved here, I saw people are just happy.

Cakrasenjaya started getting into the world of fitness, but an experience on a hike propelled him into making a healthy lifestyle top priority.

I was on a hike, Cakrasenjaya reflected. This old man, maybe 60-70 years old passed me, jogging. He waved and was like, Good day guys! See you later. I look at myself, at that point I was 32 and I was like, This guy is double my age, and just whooped me.

That day was a turning point in Cakrasenjayas life. He committed himself fully to exercising, but quickly found that his body was once again aching.

Cakrasenjaya began reading about massage therapy and its benefits, and from that point on, he knew he wanted to become a healer.

Now licensed for the past two years, Cakrasenjaya works at Jara Elements where he specializes in therapeutic and relaxation, deep tissue, pre-natal, TMJ (temporomandibular joint) treatment, headache relief and hot stone massages.

Cakrasenjaya also provides an option for a CBDtherapeutic massage, which he noted is based out of ancient healing practices.

MORE: Pueblo West welding business has big aspirations for the community

The goal of this technique, Cakrasenjaya noted, is not only to help clients relax, relieve pain, and promote healing, but it is also thought, by some, to promote healing by restoring harmony to an individuals energy fields.

The technique Cakrasenjaya uses can also assist with arthritis pain and joint inflammation, can decrease discomfort often associated with peripheral neuropathy, helps with fibromyalgia pain, and addresses skin conditions including psoriasis, eczema, acne, and even mosquito bites.

One thing Cakrasenjaya said people dont do enough of is taking care of themselves, which is why he is so passionate about massage therapy.

You tap into your spirit, your body, Cakrasenjaya said.

Going forward, Cakarsenjaya said his goal is to be the best massage therapist in the community helping the people who have made him feel as though hes found his place.

I havent been a community that supports each other so much before, Cakarsenjaya said. When I moved to Pueblo West, I felt a change. People have been so supportive; I feel like Ive found my home.

Chieftain and Pueblo West View reporter Alexis Smith can be reached by email at asmith@chieftain.com or on Twitter @smith_alexis27.

Read the original post:
Pueblo West resident utilizes massage therapy to heal mind, body and spirit - Pueblo Chieftain

Posted in Eczema | Comments Off on Pueblo West resident utilizes massage therapy to heal mind, body and spirit – Pueblo Chieftain

Tech Giants, Fearful of Proposals to Curb Them, Blitz Washington With Lobbying – The New York Times

Posted: at 6:43 am

Ms. Pelosi pushed back on Mr. Cooks concerns about the bills, according to two people with knowledge of the conversations. When Mr. Cook asked for a delay in the Judiciary Committees process of considering the bills, Ms. Pelosi pushed him to identify specific policy objections to the measures, said one of the people.

Morgan Reed, the president of the App Association, a trade organization sponsored by Apple and other tech and telecom companies, said in a letter to lawmakers on Tuesday that breaking up platforms and limiting the services they can provide for our member companies would harm your constituents.

Another outspoken critic is the Chamber of Progress, a left-leaning trade group formed in March by a former Google executive, Adam Kovacevich.

Tech had a very long political honeymoon, Mr. Kovacevich said. Many politicians and policymakers think that maybe they were too easy on tech for a long time, and now there is a countervailing desire to punish tech through either new laws or through regulatory action. And that is at odds with what consumers want.

He drafted and organized support for a letter that was sent this week urging members of the Judiciary Committee to oppose two of the bills. It warned that the bills would hurt consumers, resulting in Amazon without Prime, the iPhone without text or phone capabilities preinstalled, and Google without Maps. The letter was signed by Mr. Kovacevichs group and an unusual mix of 12 other organizations, including tech associations, free-market conservative outfits and consumer groups, most of which have received funding from Amazon, Apple, Facebook or Google.

Eli Lehrer, the president of the fiscally conservative think tank the R Street Institute, which signed the letter, criticized Republican supporters of the bills for turning their backs on their free market principles by calling on the government to use its power to intervene directly against some of the most successful companies in our countrys history.

The institute has received funding from Google, but Mr. Lehrer said the funding did not affect its stance on the legislation, as did representatives from other signatory groups.

View post:

Tech Giants, Fearful of Proposals to Curb Them, Blitz Washington With Lobbying - The New York Times

Comments Off on Tech Giants, Fearful of Proposals to Curb Them, Blitz Washington With Lobbying – The New York Times

Tech Giants Risk Fresh Tumult as Congress Hefts Antitrust Hammer – Bloomberg

Posted: at 6:43 am

A House committee will take up legislation Wednesday aimed at reining in U.S. tech giants, the first significant bipartisan push to limit the power of internet platforms, even though the measures lack a clear path to become law.

Most of the six bills to be considered by the Judiciary Committee came out of a 16-month investigation by its antitrust panel into Apple Inc., Facebook Inc., Alphabet Inc.s Google and Amazon.com Inc. and seek to address the companies dominance over markets.

Though the proposals that most threaten the companies are unlikely to become law as written, they show that lawmakers are intent on finding a way to curb the dominance of tech behemoths and preview how theyre seeking to strengthen antitrust enforcement.

For example, a bill introduced by Rhode Island Democrat David Cicilline, chair of the antitrust subcommittee, would prevent companies from giving advantage to their own services over those of a competitor on their platforms. That could threaten Googles $23 billion display-advertising business.

A proposal from Democratic Representative Pramila Jayapal of Washington state would prohibit companies from offering some services -- and could force Amazon to sell its valuable logistics network of warehouses and delivery hubs.

Its very hard to regulate a sector as large and as complex as the digital sector, said Fiona Scott Morton, who was an economist at the Justice Departments antitrust division under President Barack Obama and has also advised Amazon and Apple. There are always things to improve -- undoubtedly the Senate will have bills, well have a national conversation about these -- but the important thing is we have started.

Industry groups supported by tech companies have said that these proposals would hurt innovation and U.S. competitiveness and destroy products like iMessage and Google Maps that people like. Amazon has said the bills would hurt hundreds of thousands of sellers, including small businesses, that rely on its platform to reach consumers.

While 2021 returns vary widely for the big four in lawmakers sights, investors are hardly panicking over Congresss intentions.

Google parent Alphabet and Facebook are both outperforming broader U.S. stock benchmarks, with year-to-date gains of 40% and 24% respectively. The underperformers are Amazon and Apple, up only 7.6% and 1%.

The bipartisan support for cracking down on the tech behemoths, unusual in a year of deep political divisions, shows the degree of lawmaker anger with the industry. Still, there are notable differences. Some conservatives, including the Judiciary Committees top Republican, Representative Jim Jordan of Ohio, share that anger but say these bills arent the best way to punish tech companies for what they describe as censoring right-wing users and viewpoints like those of former President Donald Trump and his supporters.

Some pro-business Democrats have echoed calls from tech groups for the Judiciary Committee to slow down and hear from industry experts about how particular provisions could harm products that are widely used by U.S. consumers.

Read More: Antitrust Bills Have Some Democrats Asking Pelosi to Slow Down

While the antitrust package reflects a larger push in Washington to take more aggressive action to address market concentration, especially in the tech sector, its not clear that the House approach is supported by Senate Democrats, much less the 10 Republicans needed for almost any bill to pass the Senate.

Two of the measures have companion bills in the Senate, giving them a better chance of becoming law than the others. The Merger Filing Fee Modernization Act, H.R. 3843, would give the Justice Department and the Federal Trade Commission, which share antitrust enforcement, more resources to bring cases. The Senate passed its version in early June. The State Antitrust Enforcement Venue Act, H.R. 3460, would allow cases brought by state attorneys general to remain in the states where they were initially filed.

The other four bills would apply only to an online platform that has at least 50 million monthly users or at least 100,000 monthly business users, a market capitalization of more than $600 billion and is considered a critical trading partner for other companies. These criteria would apply to Facebook, Amazon, Apple and Google. When asked if they would also include Microsoft Corp., Cicilline said it would be up to the FTC and the Justice Department to declare which firms would be in scope.

Cicillines bill, H.R. 3816, cosponsored by Republican Lance Gooden of Texas, would outlaw any practice that advantages the covered platform operators own products, services, or lines of business over those of another business user. That could limit how Apple presents its own music and messaging products on iPhones because competitors including Spotify and Facebooks WhatsApp depend on mobile phones to reach consumers.

Gooden also joined Jayapal on her proposal, H.R. 3825, which would force the divestiture of entire lines of business, such as Amazons logistics services.

Read More: Amazon Could Be Forced to Sell Logistics Business Under Bill

Representative Ken Buck of Colorado, the antitrust subcommittees top Republican, and Democrat Hakeem Jeffries of New York, sponsored H.R. 3826, which would create a new merger law applying to acquisitions by the tech platforms and make it easier for enforcers to block deals they view as anticompetitive.

The committee will also consider H.R. 3849, sponsored by Representative Mary Gay Scanlon, a Pennsylvania Democrat, which aims to make it easier for users to move their data, such as photos and contacts, from one service to another.

While the Senate Judiciary Committees antitrust panel has raised some of the same issues that the House bills seek to address, Chair Amy Klobuchar has taken a broader look at concentration across the economy beyond the tech sector. She introduced a proposal in February that focuses on updating existing antitrust statutes to make it easier for enforcement agencies to bring and win cases.

Klobuchar, a Minnesota Democrat, has said shes willing to break that measure into smaller pieces that might have a better chance of getting enough bipartisan support to become law, but she hasnt joined the Houses legislative focus on a small number of powerful tech companies.

The proposals are a good first step, according to Bill Baer, who led the Justice Departments antitrust division under Obama. Baer said bringing antitrust cases can be a long and sometimes fruitless pursuit for enforcement agencies, and the House bills are an attempt to reverse decades of lax enforcement and decisions by conservative judges.

What the legislation in the House recognizes, and legislation in the Senate as well, is that we do have a monopoly problem in the tech sector, that these markets seem to allow for development of and persistence of market power, with adverse effects on competition, on the consumer, Baer said.

With assistance by David McLaughlin

Before it's here, it's on the Bloomberg Terminal.

Read the original:

Tech Giants Risk Fresh Tumult as Congress Hefts Antitrust Hammer - Bloomberg

Comments Off on Tech Giants Risk Fresh Tumult as Congress Hefts Antitrust Hammer – Bloomberg